Tankrich

Tankrich

Share this post

Tankrich
Tankrich
Windlas Biotech Ltd

Windlas Biotech Ltd

(NSE: WINDLAS)

Jun 15, 2025
∙ Paid
5

Share this post

Tankrich
Tankrich
Windlas Biotech Ltd
1
Share

To get an introduction to this sector read below

Indian Domestic CDMO Companies

Vivek Bothra
·
Jan 3
Indian Domestic CDMO Companies

[this post has interactive charts so best viewed on desktop]

Read full story

Company History and Management

Windlas Biotech Ltd, incorporated on February 19, 2001, is a leading pharmaceutical contract development and manufacturing organization (CDMO) in India, headquartered in Dehradun, Uttarakhand. It has grown to become one of the top five players in the Indian CDMO industry, with four state-of-the-art manufacturing facilities and fifth one commenced in 2025

Source : Q4,2025 Investor presentation

The management team comprises experienced professionals with significant industry expertise:

  • Hitesh Windlass: Managing Director, leading strategic initiatives.

  • Manoj Kumar Windlass: Joint Managing Director, overseeing operations.

  • Komal Gupta: CEO & CFO since 2015, driving financial strategy.

  • Vivek Dhariwal: Chairman & Independent Director, ensuring governance.

  • Other key members include Ashok Kumar Windlass (Whole Time Director), Pawan Kumar Sharma (Executive Director), and independent directors Gaurav Gulati and Srinivasan Venkataraman.

Business Model

Windlas Biotech operates primarily as a domestic CDMO, offering services from product discovery to commercial manufacturing of generic products, including complex generics. It also markets its own branded products in trade generics and over-the-counter (OTC) markets and engages in exports.

Source: Q4,2025 Investor presentation
Source : Q4,2025 Investor presentation

Revenue breakdown

Source : Q4,2025 Investor Presentation

The company serves marquee clients like Pfizer, Sanofi, and Cadila, focusing on therapeutic categories such as anti-diabetic, cardiovascular, and respiratory therapies.

Windlas Biotech is consistently profitable with decent ROCE

Source : Q4,2025 Investor presentation

Windlas Biotech maintains stable margins:

Keep reading with a 7-day free trial

Subscribe to Tankrich to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 Vivek Bothra
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share